Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
Oct 2, 2020
PARAMUS, N.J. - October 2, 2020 - (Newswire.com)
Epygenix Therapeutics, Inc., a privately-held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the first patient has been enrolled in a Phase 2, 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of EPX-100 as Adjunctive Therapy in Children with Dravet Syndrome. This Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting 24 patients to complete the study. Detailed study information is now available at clinicaltrials.gov. and dravetfoundation.org.
Dravet Syndrome is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent or prolonged seizures. Intellectual disability, behavioral abnormalities, gait and motor dysfunction, and increased mortality are commonly observed as the disease progresses. Patients suffer from life-threatening seizures that cannot be adequately controlled with available medications, and face an increased risk of SUDEP (Sudden Unexplained Death in Epilepsy), seizure-related accidents such as drowning, or infections.
Dr. Hahn-Jun Lee, M.Sc., Ph.D., President and CEO of Epygenix Therapeutics, Inc. stated, “We are very excited about the first patient enrollment, because this is one of the most significant clinical milestones for us. This opens the door to explore the efficacy for a better treatment option, and confirms our commitment to Dravet community.”
Dr. Scott C. Baraban, Ph.D., Professor & William K. Bowes Jr. Endowed Chair in Neuroscience Research at UCSF and Chair of the Scientific Advisory Board at Epygenix Therapeutics, Inc. issued a joint comment that “First patient enrollment is an extremely exciting culmination and validation of our zebrafish-based drug discovery platform. Our early promise to find new drugs for children suffering with Dravet Syndrome in a rapid and efficient manner is now coming to fruition. Working with Epygenix to move these preclinical discoveries to the clinic, in only a few short years, is a prime example of our ‘aquarium-to-bedside’ philosophy.”
Alex Yang, J.D., LLM, President and CEO of Mstone Partners Hong Kong and Chair of the Board at Epygenix Therapeutics also stated that ”We are all very excited that we can finally test our drug for its efficacy with patients. Through this clinical trial, the Company hopes to quickly provide the best drug that is both safe and efficacious for DS community.”
About Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs to treat rare and intractable genetic epilepsy in childhood, such as Dravet Syndrome. Epygenix is currently focused on developing EPX-100, -200, and -300. These candidates abolish convulsive behavior and electrographic seizure activity and were discovered in a zebrafish Dravet Syndrome model which mimics the human pathology and confirmed its validity by the human efficacy with EPX-200 and -300. For more information, please visit www.epygenix.com.
About EPX-100
EPX-100 is a first-generation antihistamine and found to be a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish models for Dravet Syndrome. Its antiepileptic action, however, is not through a histaminergic mechanism of action, but via modulation of serotonin (5HT) signaling pathways. Its safety has been confirmed with the completed Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to assess safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 in fasting healthy subjects and following a high-fat meal.
Media Contact
Hahn-Jun Lee, M.Sc., Ph.D.
201-724-1786
[email protected]
Press Release Service by Newswire.com
Original Source: Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
More News
Ukraine’s POW transfer reveal deals North Korea a propaganda blow
Ukrainian President Volodymyr Zelensky has put North Korea in a propaganda bind, analysts say, by publicly revealing that Kyiv recently transferred two North Korean prisoners of war to South Korea. The disclosure – made during Zelensky’s address to the UN General Assembly on Wednesday – directly challenges Pyongyang’s narrative that its soldiers fighting alongside Russian forces choose death over surrendering. North Korea is unlikely to acknowledge the transfer publicly, but may strengthen...
China to Send Pandas to Zoo Atlanta, Xi Says
Xi Jinping, China’s leader, said two pandas would arrive soon at Zoo Atlanta. Panda diplomacy has been a cornerstone of U.S.-China relations.
The Lucas Museum’s Architect Wants to Help You Escape From Reality
Ma Yansong, China’s reigning starchitect, lets his buildings wrapped in nature do the shouting.
Ukraine Sent Two North Korean P.O.W.s to South Korea, Zelensky Says
President Volodymyr Zelensky of Ukraine said one soldier tried to kill himself when he was captured. “This is how they raise people in the North,” he said.
The Story of Bhutan’s UN Membership
55 years ago, Bhutan joined the United Nations – with a rare show of support from bitter rivals.
Who Is Indigenous? The Politics of Tribal Identity Terminology in India and Bangladesh
Tribal people in South Asia prefer being called adivasi or original inhabitants, but nationalist forces in India and Bangladesh oppose it for different reasons.
India’s Semiconductor Journey: Old Designer, New Producer
India already has the design talent; what it needs is to turn this talent into Indian-owned companies, and to build the supplier base its fabs lack.
Singapore’s finance firms pledge to train 80,000 local staff in AI skills
Singapore’s major financial institutions have pledged to train more than 80,000 local employees in AI skills as the country moves to cushion white-collar workers from potential job disruption. A pioneer batch of 23 banks, insurers and asset managers has committed to train all their Singapore staff by 2028, and more than half of them have already gone through programmes recognised by an industry association, according to Deputy Prime Minister Gan Kim Yong. The firms would also study how jobs were...
Constitutional Reform as the Lee Jae-myung Administration’s Political Watershed
South Koreans have long discussed changing the way the presidency is set up. Should it – and can it – happen now?
Takaichi’s Pre-emptive Diplomacy: What Japan Needs From the Trump-Xi Summit
Prime Minister Takaichi made Tokyo’s concerns clear to Trump before Xi Jinping arrived in Washington. Will that actually impact the summit?
Delivered to the Wrong Address? F-35 Parts Re-routed to Hong Kong
The F-35 is a supremely advanced fighter aircraft with many proprietary components that would be of immense value to several foreign intelligence services. It is also a consumer product.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.